Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares
NEW YORK, Oct. 02, 2023 -- Immunovant, Inc. , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the closing of its...